Effect of chromium supplementation in treatment of patients with polycystic ovary syndrome candidate for IVF

Phase 3

• Conditions: Polycystic ovary syndrome.; E28.2; Polycystic

• Registration Number: IRCT20170513033941N32
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

Patients with polycystic ovary syndrome
Individuals aged 18 to 40 years old

Exclusion Criteria

Thyroid dysfunction
Diabetes or impaired glucose tolerance

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.

Secondary Outcome Measures

Name	Time	Method
Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.